Accelerating Antibody Discovery with Cell Free Protein Synthesis and Automation
- Type: Archived Webinar
- Level: Basic
- Duration: 1 hour
- PDHs: 0.00
The rapid discovery and development of antibody drugs against novel targets has never been more important. While advances in synthetic selection and antibody repertoire mining have enabled the rapid identification of candidate binders, the expression and evaluation of candidate antibodies still remains a major bottleneck in the discovery pipeline due to labor-intensive steps and process-throughput mismatches. This webinar details an innovative workflow that enables the expression and evaluation of hundreds of antibodies in a single experiment.
The new workflow consists of a cell-free DNA assembly step to generate antibody expression templates, a modified E. coli cell-free protein synthesis (CFPS) system to express antibodies, and the AlphaLISA protein-protein interaction assay to evaluate binding. The workflow is capable of processing ten times the number of candidates in less than one-third of the time when compared to comparable cell-based methods.
Scientists, professors, and researchers in the pharmaceutical sector should attend this webinar to learn more about these innovative tools. You’ll learn:
- The importance of neutralizing antibodies as a therapeutic modality for emerging viral pathogens
- The bottlenecks in current antibody discovery pipelines
- The basics of CFPS and how it can be used to screen and manufacture antibodies
- How process bottlenecks can be alleviated with CFPS combined with an Echo® acoustic liquid handler
Andrew Hunt is a fifth year PhD student working in the lab of Michael Jewett in the department of Chemical and Biological Engineering at Northwestern University. Andrew has spent his PhD developing methods that leverage cell-free protein synthesis and automation to accelerate researcher’s abilities to express and characterize proteins.
In particular, he has focused on the development of tools for rapidly characterizing protein-protein interactions for a variety of different applications. Recently, he has applied these tools to the expression and evaluation of SARS-CoV-2 neutralizing...Read more
Alex Pierson is the Technical Product Manager for the Access Solutions Group at Beckman Coulter, working to grow the continued success of the Beckman Coulter Access Systems and Biomek Integrated Solutions. A recent effort includes the new Echo into the Biomek i-Series, a platform which benefits from the strengths of both liquid handlers.
Alex has a Masters Degree in Biology with research in yeast genetics and molecular biology, and continues to leverage his years of experience and customer relationships as an Echo Field Applications Specialist and support of researchers in...Read more
|AIChE Graduate Student Members||Free|
|AIChE Undergraduate Student Members||Free|